PortfoliosLab logoPortfoliosLab logo
ZVRA vs. XERS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ZVRA vs. XERS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zevra Therapeutics Inc. (ZVRA) and Xeris Biopharma Holdings, Inc. (XERS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ZVRA achieves a 18.42% return, which is significantly higher than XERS's -21.27% return.


ZVRA

1D
-5.01%
1M
-5.69%
YTD
18.42%
6M
21.81%
1Y
20.16%
3Y*
25.02%
5Y*
-1.29%
10Y*
-21.32%

XERS

1D
0.49%
1M
-2.98%
YTD
-21.27%
6M
-5.07%
1Y
38.57%
3Y*
27.95%
5Y*
8.82%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ZVRA vs. XERS - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
ZVRA
Zevra Therapeutics Inc.
18.42%7.43%27.33%42.70%-47.30%-22.23%84.70%-78.71%-71.52%
XERS
Xeris Biopharma Holdings, Inc.
-21.27%131.56%44.26%76.69%-54.61%-40.45%-30.21%-58.53%-15.92%

Correlation

The correlation between ZVRA and XERS is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.36

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Jun 22, 2018

0.24

The correlation between ZVRA and XERS shifts across timeframes, from 0.24 (all time) to 0.36 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ZVRA:

$639.05M

XERS:

$1.10B

EPS

ZVRA:

$2.16

XERS:

$0.07

PE Ratio

ZVRA:

4.91

XERS:

88.94

PS Ratio

ZVRA:

4.98

XERS:

3.39

PB Ratio

ZVRA:

3.11

XERS:

84.37

Total Revenue (TTM)

ZVRA:

$122.29M

XERS:

$314.85M

Gross Profit (TTM)

ZVRA:

$104.94M

XERS:

$187.04M

EBITDA (TTM)

ZVRA:

$149.15M

XERS:

$41.72M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ZVRA vs. XERS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZVRA
ZVRA Risk / Return Rank: 5353
Overall Rank
ZVRA Sharpe Ratio Rank: 5454
Sharpe Ratio Rank
ZVRA Sortino Ratio Rank: 5353
Sortino Ratio Rank
ZVRA Omega Ratio Rank: 5252
Omega Ratio Rank
ZVRA Calmar Ratio Rank: 5353
Calmar Ratio Rank
ZVRA Martin Ratio Rank: 5151
Martin Ratio Rank

XERS
XERS Risk / Return Rank: 6161
Overall Rank
XERS Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
XERS Sortino Ratio Rank: 6262
Sortino Ratio Rank
XERS Omega Ratio Rank: 6363
Omega Ratio Rank
XERS Calmar Ratio Rank: 6060
Calmar Ratio Rank
XERS Martin Ratio Rank: 5757
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZVRA vs. XERS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Xeris Biopharma Holdings, Inc. (XERS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ZVRAXERSDifference
Sharpe ratioReturn per unit of total volatility

-0.36

Sortino ratioReturn per unit of downside risk

-0.40

Omega ratioGain probability vs. loss probability

1.12

1.18

-0.06

Calmar ratioReturn relative to maximum drawdown

0.47

0.83

-0.37

Martin ratioReturn relative to average drawdown

0.81

1.50

-0.69

ZVRA vs. XERS - Sharpe Ratio Comparison

The current ZVRA Sharpe Ratio is 0.34, which is lower than the XERS Sharpe Ratio of 0.70. The chart below compares the historical Sharpe Ratios of ZVRA and XERS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ZVRAXERSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.34

0.70

-0.36

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.02

0.13

-0.15

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.26

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.27

-0.18

-0.10

Drawdowns

ZVRA vs. XERS - Drawdown Comparison

The maximum ZVRA drawdown since its inception was -99.27%, roughly equal to the maximum XERS drawdown of -96.22%. Use the drawdown chart below to compare losses from any high point for ZVRA and XERS.


Loading charts...

Drawdown Indicators


ZVRAXERSDifference

Max Drawdown

Largest peak-to-trough decline

-99.27%

-96.22%

-3.05%

Max Drawdown (1Y)

Largest decline over 1 year

-43.47%

-46.57%

+3.10%

Max Drawdown (3Y)

Largest decline over 3 years

-43.47%

-50.67%

+7.20%

Max Drawdown (5Y)

Largest decline over 5 years

-74.01%

-78.59%

+4.58%

Max Drawdown (10Y)

Largest decline over 10 years

-97.85%

Current Drawdown

Current decline from peak

-97.19%

-77.30%

-19.89%

Average Drawdown

Average peak-to-trough decline

-86.40%

-79.05%

-7.35%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.86%

25.80%

-0.94%

Volatility

ZVRA vs. XERS - Volatility Comparison

Zevra Therapeutics Inc. (ZVRA) has a higher volatility of 16.48% compared to Xeris Biopharma Holdings, Inc. (XERS) at 13.18%. This indicates that ZVRA's price experiences larger fluctuations and is considered to be riskier than XERS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ZVRAXERSDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.48%

13.18%

+3.30%

Volatility (6M)

Calculated over the trailing 6-month period

35.94%

33.61%

+2.33%

Volatility (1Y)

Calculated over the trailing 1-year period

60.02%

55.57%

+4.45%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

60.16%

68.50%

-8.34%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.28%

79.16%

+2.12%

Dividends

ZVRA vs. XERS - Dividend Comparison

Neither ZVRA nor XERS has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ZVRA vs. XERS - Financials Comparison

This section allows you to compare key financial metrics between Zevra Therapeutics Inc. and Xeris Biopharma Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
36.22M
83.13M
(ZVRA) Total Revenue
(XERS) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ZVRA and XERS have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ZVRA has higher volatility (16.48%) compared to XERS (13.18%). In terms of maximum drawdown, ZVRA dropped -99.27% vs XERS's -96.22%.

XERS currently has the higher Sharpe Ratio (0.70 vs 0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ZVRA and XERS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer